作者
Matthew MY Lee, Katriona JM Brooksbank, Kirsty Wetherall, Kenneth Mangion, Giles Roditi, Ross T Campbell, Colin Berry, Victor Chong, Liz Coyle, Kieran F Docherty, John G Dreisbach, Catherine Labinjoh, Ninian N Lang, Vera Lennie, Alex McConnachie, Clare L Murphy, Colin J Petrie, John R Petrie, Iain A Speirits, Steven Sourbron, Paul Welsh, Rosemary Woodward, Aleksandra Radjenovic, Patrick B Mark, John JV McMurray, Pardeep S Jhund, Mark C Petrie, Naveed Sattar
发表日期
2021/2/9
期刊
Circulation
卷号
143
期号
6
页码范围
516-525
出版商
Lippincott Williams & Wilkins
简介
Background
Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF). However, their effects on cardiac structure and function in HFrEF are uncertain.
Methods
We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF trial [Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus, or Prediabetes, and Heart Failure]) to investigate the cardiac effects of empagliflozin in patients in New York Heart Association functional class II to IV with a left ventricular (LV) ejection fraction ≤40% and type 2 diabetes or prediabetes. Patients were randomly assigned 1:1 to empagliflozin 10 mg once daily or placebo, stratified by age (<65 and ≥65 years) and glycemic status (diabetes or prediabetes). The coprimary …
学术搜索中的文章
MMY Lee, KJM Brooksbank, K Wetherall, K Mangion… - Circulation, 2021